ArticleInternational journal of cardiology2014
Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography.
Article in International journal of cardiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02383771 (Reversal of the Anti-platelet Effects of Ticagrelor in Healthy Persons and Patients With Coronary Artery Disease), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Reversal of the Anti-platelet Effects of Ticagrelor in Healthy Persons and Patients With Coronary Artery Disease
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- The impact of direct oral anticoagulants on viscoelastic testing - A systematic review.Frontiers in cardiovascular medicine · 2022Pooled it
- The Impact of platelet-fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease.Journal of thrombosis and thrombolysis · 2020Article
- Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study.Journal of thrombosis and thrombolysis · 2020Article
- Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial.Advances in therapy · 2020Article
- The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review.International journal of emergency medicine · 2018Review
- Role of Thromboelastography and Rotational Thromboelastometry in the Management of Cardiovascular Diseases.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2018Review
- Pharmacological reversal of the direct oral anticoagulants-A comprehensive review of the literature.Research and practice in thrombosis and haemostasis · 2018Review
- In vitro and ex vivo Measurement of Prophylactic Dabigatran Concentrations with a New Ecarin-Based Thromboelastometry Test.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2017Article
- Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal.Critical care (London, England) · 2016Review
- In vitro reversal of supratherapeutic rivaroxaban levels with coagulation factor concentrates.Blood transfusion = Trasfusione del sangue · 2016Article
- Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting.Anesthesia and analgesia · 2016Review
- The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition.Critical care (London, England) · 2016Article
- Who, when, and how to reverse non-vitamin K oral anticoagulants.Journal of thrombosis and thrombolysis · 2016Review
- Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy.Current drug targets · 2016Review
- Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents.Journal of thrombosis and thrombolysis · 2015Review
- Global assays and the management of oral anticoagulation.Thrombosis journal · 2015Article
- Association Between Thrombogenicity Indices and Coronary Microvascular Dysfunction in Patients With Acute Myocardial Infarction.JACC. Basic to translational scienceArticle
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDabigatran etexilate, a pro-drug of a direct thrombin inhibitor, was approved a few years ago for non-valvular atrial fibrillation and deep venous thrombosis. Rapid monitoring of the dabigatran level is essential in trauma and bleeding patients but the traditional plasma-based assays may not sufficiently display the effect. Furthermore, no antidote exists and reversal of the anticoagulant effect is impossible or difficult. The present study investigated the in vitro effect of dabigatran on whole blood thromboelastography (TEG) and its reversal by recombinant activated factor VII and prothrombin complex concentrate.
methodsBlood was collected from 10 healthy donors and spiked in vitro with therapeutic doses of dabigatran to a plasma concentration of 200 ng/ml, followed by therapeutic doses of recombinant activated factor VII (corresponding to 100 μg/kg) and prothrombin complex concentrate (corresponding to 50 IE/kg) and evaluated by TEG.
resultsCompared to baseline, dabigatran changed all TEG parameters in a hypocoagulable direction corresponding to increased R time and time to maximum rate of thrombus generation, reduced angle, A5, A10, maximum amplitude and maximum rate of thrombin formation. Recombinant activated factor VII had a procoagulant effect on the majority of the investigated TEG parameters when added to dabigatran spiked samples. Prothrombin complex concentrate appeared not to have a procoagulant effect on TEG even when the heparin content in the formulation was neutralized by heparinase.
conclusionsTEG displays the presence of dabigatran in whole blood in vitro and the anticoagulant effect of dabigatran is partly reversed by spiking with recombinant activated factor VII.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.